Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-01-06 00:00:00 ET · period of report 2025-12-31 · accession 0002001011-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | 2025-12-31 | LGND | Espinoza Octavio | CFO | J - Other | $95.68 | +8 | 28.6K | +0.0% | +$765.44 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | J | A | 8 | $95.68 | 28,575 | D | — | — |